Bayer's KERENDIA shows kidney benefits in non-diabetic patients
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures rise on tech buying, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil falls as traders digest escalation in US-Iran strikes
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- SAP stock dips after Oracle's massive AI spending plans
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- UBS sees generational semiconductor boom, highlights stock winners
Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disea
June 5, 2026 6:40 AM EDTInvestigational results from FIND-CKD provide full efficacy and safety data and is the fifth consecutive Phase III clinical trial where KERENDIA met its primary endpointadding to a clinical trial program of more than 20,000 patients across multiple patient populations with heart and kidney diseases, now with additional data in a different patient population.1
KERENDIA is currently approved by the FDA for use in adults with chronic kidney disease (CKD) associated with type 2 diabetes (T2D), as well as adults with heart failure (HF) with left ventricular ejection fraction (LVEF) 40%.2
WHIPPANY, N.J.--(BUSINESS... More
